Brief: Reata Pharmaceuticals Announces FDA Approval Of Skyclarys™ (Omavaloxolone), The First And Only Drug Indicated For Patients With Friedreich’S Ataxia

Reata Pharmaceuticals

28/02/2023 22:26

Feb 28 (Reuters) - Reata Pharmaceuticals Inc  RETA.O :
    * REATA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SKYCLARYS™
(OMAVALOXOLONE), THE FIRST AND ONLY DRUG INDICATED FOR PATIENTS
WITH FRIEDREICH’S ATAXIA
    * REATA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SKYCLARYS™
(OMAVALOXOLONE), THE FIRST AND ONLY DRUG INDICATED FOR PATIENTS
WITH FRIEDREICH’S ATAXIA
    * REATA PHARMACEUTICALS INC - RARE PEDIATRIC DISEASE
PRIORITY
REVIEW VOUCHER GRANTED

Source text for Eikon:  ID:nBw29HBy9a 
Further company coverage:  RETA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))